Biodexa Pharmaceuticals (BDRX) Invested Capital (2015 - 2025)
Biodexa Pharmaceuticals (BDRX) posted Invested Capital of $5.6 million for Q4 2025, up 732.7% sequentially from $668356.9 in Q2 2025, and up 46.79% YoY from $3.8 million in Q4 2024.
Biodexa Pharmaceuticals (BDRX) Invested Capital (2015 - 2025) Analysis & Trends
Biodexa Pharmaceuticals has reported Invested Capital for 11 years, with the latest figure at $5.6 million in Q4 2025.
- Quarterly Invested Capital rose 46.79% year-over-year to $5.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $10.2 million (up 2.91% YoY) and the FY2025 annual result came in at $5.5 million, up 45.5% from the prior year.
- Invested Capital rose to $5.6 million in Q4 2025 per BDRX's latest filing, from $668356.9 in the prior quarter.
- Over five years, Invested Capital peaked at $5.7 million in Q4 2023 and troughed at $205223.6 in Q2 2023.
- A 5-year average of $2.3 million and a median of $1.3 million in 2021 frame the typical range for Invested Capital.
- The sharpest annual moves came in 2022 and 2023: Invested Capital slumped 53.23% in 2022, then jumped 590.12% in 2023.
- Over 5 years, Invested Capital stood at $1.8 million in 2021, then plunged by 53.23% to $831606.2 in 2022, then soared by 590.12% to $5.7 million in 2023, then slumped by 33.94% to $3.8 million in 2024, then jumped by 46.79% to $5.6 million in 2025.
- According to Business Quant data, Invested Capital over the past three periods registered $5.6 million, $668356.9, and $3.8 million for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Invested Cap. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 37.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 190.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.45 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 380.00 Mn |
| 10 | Biodexa Pharmaceuticals | 64,325.41 | -11.29 Mn | - | 81,140.14 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 5.57 Mn |
| Jun 30, 2025 | 668,356.89 |
| Dec 31, 2024 | 3.79 Mn |
| Jun 30, 2024 | 219,626.41 |
| Dec 31, 2023 | 5.74 Mn |
| Jun 30, 2023 | 205,223.56 |
| Dec 31, 2022 | 831,606.18 |
| Dec 31, 2021 | 1.78 Mn |
| Dec 31, 2020 | 2.40 Mn |
| Dec 31, 2019 | 8.67 Mn |
| Dec 31, 2018 | 1.61 Mn |
| Dec 31, 2017 | 8.69 Mn |
| Dec 31, 2016 | 28,594.11 |
| Dec 31, 2015 | 8.29 Mn |